OpenAI’s Sam Altman is becoming one of the most powerful people on Earth. We should be very afraid
By Gary Marcus,
The Guardian
| 08. 03. 2024
Image by TechCrunch from Flickr licensed under CC by 2.0
On 16 May 2023, Sam Altman, OpenAI’s charming, softly spoken, eternally optimistic billionaire CEO, and I stood in front of the US Senate judiciary subcommittee meeting on AI oversight. We were in Washington DC, and it was at the height of AI mania. Altman, then 38, was the poster boy for it all.
Raised in St Louis, Missouri, Altman was the Stanford dropout who had become the president of the massively successful Y Combinator startup incubator before he was 30. A few months before the hearing, his company’s product ChatGPT had taken the world by storm. All through the summer of 2023, Altman was treated like a Beatle, stopping by DC as part of a world tour, meeting prime ministers and presidents around the globe. US Senator Kyrsten Sinema gushed: “I’ve never met anyone as smart as Sam… He’s an introvert and shy and humble… But… very good at forming relationships with people on the Hill and… can help folks in government understand AI.” Glowing portraits at the...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...